Wiesner 1990.

Methods	Randomised clinical trial.
Participants	Country: USA. Number randomised: 40. Post‐randomisation dropouts: 11 (27.5%). Revised sample size: 29. Mean age: 46 years. Females: 28 (96.6%). Symptomatic participants: not stated. AMA positive: not stated. Responders: not stated. Median follow‐up period (for all groups): 35 months. Inclusion criteria Symptom status: not stated. AMA status: not stated. Response status: not stated. Exclusion criteria Cirrhosis or advanced liver disease. Renal dysfunction. Uncontrolled hypertension. Neoplastic disease. Skin cancer. Previous immunosuppressive therapy. Other liver diseases.
Interventions	Participants were randomly assigned to 2 groups. Group 1: ciclosporin (n = 19). Further details: ciclosporin: 4 mg/kg/day. Group 2: placebo (n = 10).
Outcomes	Mortality, adverse events, liver transplantation.
Notes	Reasons for post‐randomisation dropouts: follow‐up < 1 year.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: information not available.
Allocation concealment (selection bias)	Unclear risk	Comment: information not available.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Comment: identical placebo used in this double‐blind trial.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Comment: identical placebo used in this double‐blind trial.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: information not available.
Selective reporting (reporting bias)	Low risk	Comment: mortality and morbidity reported.
For‐profit bias	High risk	Quote: "Supported by a grant from Sandoz and by the Mayo foundation".
Other bias	Low risk	Comment: no other source of bias.